BR0010338A - Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound - Google Patents
Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compoundInfo
- Publication number
- BR0010338A BR0010338A BR0010338-1A BR0010338A BR0010338A BR 0010338 A BR0010338 A BR 0010338A BR 0010338 A BR0010338 A BR 0010338A BR 0010338 A BR0010338 A BR 0010338A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- cck
- preparation
- disease
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSTO ENANCIOMERICAMENTE ENRIQUECIDO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR UMA DOENçA OU CONDIçãO MEDIADA POR CCK-A, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Um composto enanciomericamente enriquecido de Fórmula (I) é exposto, processos para a sua preparação, composições farmacêuticas que o contêm e o uso dos mesmos, para o tratamento de doenças ou condições mediadas por CCK-A, tais como obesidade."ENANCIOMERICALLY ENRICHED COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE OR CONDITION MEDIATED BY CCK-A, USE OF A COMPOUND, AND, PROCESS FOR THE PREPARATION OF A COMPOUND". An enanciomerically enriched compound of Formula (I) is exposed, processes for its preparation, pharmaceutical compositions containing it and the use of them, for the treatment of diseases or conditions mediated by CCK-A, such as obesity.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9910366.5A GB9910366D0 (en) | 1999-05-06 | 1999-05-06 | 1,5-Benzodiazepine Derivatives |
GBGB0008179.4A GB0008179D0 (en) | 2000-04-05 | 2000-04-05 | Chemical process |
PCT/EP2000/003982 WO2000068209A2 (en) | 1999-05-06 | 2000-05-04 | 1,5-benzodiazepine derivatives as cck-a receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0010338A true BR0010338A (en) | 2002-02-13 |
Family
ID=26244033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0010338-1A BR0010338A (en) | 1999-05-06 | 2000-05-04 | Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1212305A2 (en) |
JP (1) | JP2002544200A (en) |
KR (1) | KR20020012567A (en) |
CN (1) | CN1161345C (en) |
AR (1) | AR022044A1 (en) |
AU (1) | AU4754800A (en) |
BR (1) | BR0010338A (en) |
CA (1) | CA2370801A1 (en) |
CO (1) | CO5170461A1 (en) |
CZ (1) | CZ20013988A3 (en) |
HK (1) | HK1046138A1 (en) |
HU (1) | HUP0201181A3 (en) |
IL (1) | IL146124A0 (en) |
MX (1) | MXPA01011267A (en) |
MY (1) | MY138319A (en) |
NO (1) | NO20015397L (en) |
NZ (1) | NZ515048A (en) |
PE (1) | PE20010110A1 (en) |
PL (1) | PL351546A1 (en) |
TR (1) | TR200103169T2 (en) |
WO (1) | WO2000068209A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035793A2 (en) * | 2003-10-09 | 2005-04-21 | Decode Genetics Ehf. | Cckar markers and haplotypes associated with extreme weight conditions |
GEP20094723B (en) | 2004-05-25 | 2009-07-10 | Pfizer Prod Inc | Tetraazabenzo [e] azulene derivatives and analogs thereof |
BR112022006546A2 (en) | 2019-10-07 | 2022-08-30 | Kallyope Inc | GPR119 AGONISTS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9307833D0 (en) * | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
-
2000
- 2000-05-03 AR ARP000102119A patent/AR022044A1/en unknown
- 2000-05-04 TR TR2001/03169T patent/TR200103169T2/en unknown
- 2000-05-04 NZ NZ515048A patent/NZ515048A/en unknown
- 2000-05-04 PL PL00351546A patent/PL351546A1/en not_active Application Discontinuation
- 2000-05-04 WO PCT/EP2000/003982 patent/WO2000068209A2/en not_active Application Discontinuation
- 2000-05-04 CO CO00031982A patent/CO5170461A1/en not_active Application Discontinuation
- 2000-05-04 PE PE2000000415A patent/PE20010110A1/en not_active Application Discontinuation
- 2000-05-04 IL IL14612400A patent/IL146124A0/en unknown
- 2000-05-04 BR BR0010338-1A patent/BR0010338A/en not_active IP Right Cessation
- 2000-05-04 CZ CZ20013988A patent/CZ20013988A3/en unknown
- 2000-05-04 CA CA002370801A patent/CA2370801A1/en not_active Abandoned
- 2000-05-04 JP JP2000617189A patent/JP2002544200A/en active Pending
- 2000-05-04 MX MXPA01011267A patent/MXPA01011267A/en not_active Application Discontinuation
- 2000-05-04 KR KR1020017014075A patent/KR20020012567A/en not_active Application Discontinuation
- 2000-05-04 EP EP00929488A patent/EP1212305A2/en not_active Withdrawn
- 2000-05-04 HU HU0201181A patent/HUP0201181A3/en unknown
- 2000-05-04 MY MYPI20001917A patent/MY138319A/en unknown
- 2000-05-04 CN CNB008099324A patent/CN1161345C/en not_active Expired - Fee Related
- 2000-05-04 AU AU47548/00A patent/AU4754800A/en not_active Abandoned
-
2001
- 2001-11-05 NO NO20015397A patent/NO20015397L/en not_active Application Discontinuation
-
2002
- 2002-10-23 HK HK02107684.4A patent/HK1046138A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002544200A (en) | 2002-12-24 |
MXPA01011267A (en) | 2002-05-06 |
MY138319A (en) | 2009-05-29 |
WO2000068209A3 (en) | 2001-03-01 |
WO2000068209A2 (en) | 2000-11-16 |
EP1212305A2 (en) | 2002-06-12 |
KR20020012567A (en) | 2002-02-16 |
TR200103169T2 (en) | 2002-04-22 |
HK1046138A1 (en) | 2002-12-27 |
CA2370801A1 (en) | 2000-11-16 |
HUP0201181A3 (en) | 2003-10-28 |
NZ515048A (en) | 2004-01-30 |
CZ20013988A3 (en) | 2002-02-13 |
AR022044A1 (en) | 2002-09-04 |
PE20010110A1 (en) | 2001-03-05 |
CO5170461A1 (en) | 2002-06-27 |
IL146124A0 (en) | 2002-07-25 |
AU4754800A (en) | 2000-11-21 |
CN1161345C (en) | 2004-08-11 |
CN1362949A (en) | 2002-08-07 |
PL351546A1 (en) | 2003-05-05 |
NO20015397D0 (en) | 2001-11-05 |
HUP0201181A2 (en) | 2002-12-28 |
NO20015397L (en) | 2001-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9509683A (en) | Compounds and processes for treating a clinical condition in a mammal for treating a hyperlipidemic condition in a manifer and for preparing a compound | |
BR0116370A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient. | |
BR0313266A (en) | Compounds, their preparation and use processes, pharmaceutical formulation and methods for preventing and / or treating a mglur5 receptor mediated disorder and inhibiting mglur5 receptor activation | |
BR9911488A (en) | Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound | |
AR014261A1 (en) | BENZOTIAZEPINE HYPOLIPIDEMIC COMPOUNDS, COMPOSITIONS AND PROCESS FOR PREPARATION | |
BR0108600A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease | |
BR9502707A (en) | Compound pharmaceutical composition and method for treating a condition | |
BRPI9710372B8 (en) | compound, and, pharmaceutical composition. | |
BR0010555A (en) | Neuraminidase Inhibitors | |
BR9808953A (en) | Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition | |
UY26130A1 (en) | COMPOUNDS TO TREAT OBESITY | |
BR9713465A (en) | Cytically substituted amine metallotprotease inhibitors | |
BRPI0411255A (en) | compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound | |
BR0209127A (en) | compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds | |
BR0209129A (en) | Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds. | |
BRPI0417376A (en) | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use | |
BR0206514A (en) | Compound, method of treating a human or animal suffering from migraine, use of the compound, pharmaceutical composition, and process for preparing a compound | |
KR950031060A (en) | Pharmaceutical composition for the treatment of osteoporosis | |
BRPI0114344B8 (en) | retinoid compound, its use, its pharmaceutical composition and its preparation process | |
DE69413829D1 (en) | ANTIGLUCOCORTICOIDSTEROIDS FOR TREATING ANXIETY DISORDERS | |
BR0209128A (en) | Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds | |
BR9809234A (en) | Compound, pharmaceutical composition, use of a compound, processes to treat or prevent diseases of the endocrinological system, to manufacture a drug, to prepare a compound and a set, and use of it. | |
DE69918972D1 (en) | USE OF NMDA ANTAGONISTS AND / OR SODIUM CHANNEL ANTAGONISTS FOR TREATING INFLAMMABLE DISEASES | |
BR9909870A (en) | Pyrrolidines as inhibitors of neuraminidases | |
BR0010338A (en) | Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009. |